New radiation method aims to cut side effects in prostate cancer treatment

NCT ID NCT05668351

Ongoing Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new way to deliver high-dose radiation (SABR) for low- and intermediate-risk prostate cancer. The technique, called SUPR-SABR, is designed to avoid the urethra, rectum, and pudendal artery to reduce urinary and bowel side effects. About 42 men will receive five radiation sessions over 1-2 weeks, and researchers will track their quality of life and side effects for two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic ablative body radiotherapy (SABR) with urethra, pudendal artery, and rectum sparing
What this could lead to: If successful, this approach could reduce urinary and bowel side effects from radiation therapy for prostate cancer, making treatment more tolerable.
What could go wrong: This is a small, early-phase trial with only 42 participants and no comparison group. It is not yet known if the new technique controls cancer as well as standard SABR.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Medical University of South Carolina Hollings Cancer Center

Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.